tenet healthcare corp. - THC
THC
Close Chg Chg %
147.93 -4.36 -2.95%
Closed Market
143.57
-4.36 (2.95%)
Volume: 2.57M
Last Updated:
Nov 22, 2024, 3:59 PM EDT
Company Overview: tenet healthcare corp. - THC
THC Key Data
| Open $144.69 | Day Range 141.09 - 145.63 |
| 52 Week Range 65.90 - 170.88 | Market Cap $14.07B |
| Shares Outstanding 95.10M | Public Float 93.11M |
| Beta 2.15 | Rev. Per Employee N/A |
| P/E Ratio 4.73 | EPS $31.61 |
| Yield 0.00% | Dividend $0.01 |
| EX-DIVIDEND DATE Mar 13, 2000 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.52M |
THC Performance
| 1 Week | -4.78% | ||
| 1 Month | 5.83% | ||
| 3 Months | -10.10% | ||
| 1 Year | 117.53% | ||
| 5 Years | 370.63% |
THC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
22
Full Ratings ➔
About tenet healthcare corp. - THC
Tenet Healthcare Corp. engages in the provision of healthcare services. It operates through the Hospital Operations and Other, and Ambulatory Care segments. The Hospital Operations and Other segment is composed of acute care hospitals, ancillary outpatient facilities, urgent care centers, micro hospitals and physician practices. The Ambulatory Care segment includes the operations of the USPI joint venture and the company's nine Aspen facilities in the United Kingdom. The company was founded in 1969 and is headquartered in Dallas, TX.
THC At a Glance
Tenet Healthcare Corp.
14201 Dallas Parkway
Dallas, Texas 75254
| Phone | 1-469-893-2200 | Revenue | 20.55B | |
| Industry | Hospital/Nursing Management | Net Income | 611.00M | |
| Sector | Health Services | 2023 Sales Growth | 7.166% | |
| Fiscal Year-end | 12 / 2024 | Employees | 106,500 | |
| View SEC Filings |
THC Valuation
| P/E Current | 4.857 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 12.962 |
| Price to Sales Ratio | 0.385 |
| Price to Book Ratio | 4.697 |
| Price to Cash Flow Ratio | 3.336 |
| Enterprise Value to EBITDA | 8.13 |
| Enterprise Value to Sales | 1.304 |
| Total Debt to Enterprise Value | 0.605 |
THC Efficiency
| Revenue/Employee | 192,938.967 |
| Income Per Employee | 5,737.089 |
| Receivables Turnover | 5.146 |
| Total Asset Turnover | 0.741 |
THC Liquidity
| Current Ratio | 1.506 |
| Quick Ratio | 1.419 |
| Cash Ratio | 0.258 |
THC Profitability
| Gross Margin | 11.811 |
| Operating Margin | 11.811 |
| Pretax Margin | 7.869 |
| Net Margin | 2.974 |
| Return on Assets | 2.203 |
| Return on Equity | 44.436 |
| Return on Total Capital | 3.429 |
| Return on Invested Capital | 3.53 |
THC Capital Structure
| Total Debt to Total Equity | 1,008.271 |
| Total Debt to Total Capital | 90.977 |
| Total Debt to Total Assets | 57.265 |
| Long-Term Debt to Equity | 988.122 |
| Long-Term Debt to Total Capital | 89.159 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Tenet Healthcare Corp. - THC
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 17.64B | 19.48B | 19.17B | 20.55B | |
Sales Growth
| -4.54% | +10.46% | -1.60% | +7.17% | |
Cost of Goods Sold (COGS) incl D&A
| 16.35B | 17.23B | 16.90B | 18.12B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 857.00M | 855.00M | 841.00M | 870.00M | |
Depreciation
| 685.00M | 667.00M | 669.00M | 696.00M | |
Amortization of Intangibles
| 172.00M | 188.00M | 172.00M | 174.00M | |
COGS Growth
| -2.65% | +5.33% | -1.89% | +7.22% | |
Gross Income
| 1.29B | 2.26B | 2.27B | 2.43B | |
Gross Income Growth
| -23.41% | +75.66% | +0.66% | +6.73% | |
Gross Profit Margin
| +7.29% | +11.59% | +11.86% | +11.81% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| - | 28.00M | 41.00M | 56.00M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| - | 28.00M | 41.00M | 56.00M | |
SGA Growth
| - | - | +46.43% | +36.59% | - |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 650.00M | 275.00M | 405.00M | 195.00M | |
EBIT after Unusual Expense
| 608.00M | 1.94B | 1.81B | 2.23B | |
Non Operating Income/Expense
| 1.07B | 868.00M | 421.00M | 286.00M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| 169.00M | 218.00M | 216.00M | 228.00M | |
Interest Expense
| 1.00B | 923.00M | 890.00M | 901.00M | |
Interest Expense Growth
| +1.83% | -7.98% | -3.58% | +1.24% | |
Gross Interest Expense
| 1.00B | 923.00M | 890.00M | 901.00M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 671.00M | 1.89B | 1.34B | 1.62B | |
Pretax Income Growth
| +126.69% | +181.37% | -28.81% | +20.31% | |
Pretax Margin
| +3.80% | +9.69% | +7.01% | +7.87% | |
Income Tax
| (97.00M) | 411.00M | 344.00M | 306.00M | |
Income Tax - Current - Domestic
| 30.00M | 161.00M | 135.00M | 254.00M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (127.00M) | 250.00M | 209.00M | 52.00M | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| 169.00M | 218.00M | 216.00M | 228.00M | |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 768.00M | 1.48B | 1.00B | 1.31B | |
Minority Interest Expense
| 369.00M | 562.00M | 590.00M | 700.00M | |
Net Income
| 399.00M | 915.00M | 410.00M | 611.00M | |
Net Income Growth
| +264.20% | +129.32% | -55.19% | +49.02% | |
Net Margin Growth
| +2.26% | +4.70% | +2.14% | +2.97% | |
Extraordinaries & Discontinued Operations
| - | - | (1.00M) | 1.00M | - |
Discontinued Operations
| - | - | (1.00M) | 1.00M | - |
Net Income After Extraordinaries
| 399.00M | 914.00M | 411.00M | 611.00M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 399.00M | 914.00M | 411.00M | 611.00M | |
EPS (Basic)
| 3.7996 | 8.5554 | 3.8437 | 6.0115 | |
EPS (Basic) Growth
| +269.34% | +125.17% | -55.07% | +56.40% | |
Basic Shares Outstanding
| 105.01M | 106.83M | 106.93M | 101.64M | |
EPS (Diluted)
| 3.7548 | 8.4184 | 3.7189 | 5.8302 | |
EPS (Diluted) Growth
| +267.34% | +124.20% | -55.82% | +56.77% | |
Diluted Shares Outstanding
| 106.26M | 108.57M | 110.52M | 104.80M | |
EBITDA
| 2.12B | 3.07B | 3.06B | 3.30B | |
EBITDA Growth
| -16.37% | +45.30% | -0.46% | +7.78% | |
EBITDA Margin
| +11.99% | +15.77% | +15.95% | +16.05% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 188.316 | |
| Number of Ratings | 22 | Current Quarters Estimate | 2.949 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 11.324 | |
| Last Quarter’s Earnings | 2.93 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 6.98 | Next Fiscal Year Estimate | 11.571 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 11 | 14 | 14 |
| Mean Estimate | 2.95 | 3.18 | 11.32 | 11.57 |
| High Estimates | 3.08 | 3.77 | 11.52 | 13.00 |
| Low Estimate | 2.73 | 2.77 | 10.40 | 9.85 |
| Coefficient of Variance | 3.27 | 10.03 | 2.47 | 6.82 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 14 | 16 | 16 |
| OVERWEIGHT | 5 | 3 | 4 |
| HOLD | 2 | 2 | 3 |
| UNDERWEIGHT | 1 | 1 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Buy | Buy |
SEC Filings for Tenet Healthcare Corp. - THC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Tenet Healthcare Corp. - THC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 13, 2024 | Saumya Sutaria Chairman & CEO; Director | 271,521 | Bona fide gift | 0.00 |
| Jun 13, 2024 | Richard W. Fisher Director | 16,227 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $132.24 per share | 2,145,858.48 |
| Jun 13, 2024 | Saumya Sutaria Chairman & CEO; Director | 100,000 | Bona fide gift | 0.00 |
| Jun 4, 2024 | Christopher S. Lynch Director | 14,759 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $133.83 per share | 1,975,196.97 |
| Jun 4, 2024 | Joseph Robert Kerrey Director | 54,367 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $133.2 per share | 7,241,684.40 |
| Jun 4, 2024 | Joseph Robert Kerrey Director | 46,403 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $134.65 per share | 6,248,163.95 |
| Jun 4, 2024 | Joseph Robert Kerrey Director | 36,903 | Bona fide gift | 0.00 |
| Jun 4, 2024 | Joseph Robert Kerrey Director | 9,500 | Bona fide gift | 0.00 |
| Jun 4, 2024 | Joseph Robert Kerrey Director | 801 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $133.3 per share | 106,773.30 |
| Jun 4, 2024 | Joseph Robert Kerrey Director | 104 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $134.44 per share | 13,981.76 |
| Jun 4, 2024 | Joseph Robert Kerrey Director | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $135.17 per share | 0.00 |
| May 29, 2024 | Roy Dean Blunt Director | 1,551 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 29, 2024 | Richard J. Mark Director | 1,551 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 29, 2024 | Cecil D. Haney Director | 1,551 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 29, 2024 | Nadja Y. West Director | 1,551 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 29, 2024 | Vineeta Agarwala Director | 1,551 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 29, 2024 | Tammy Romo Director | 1,551 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 29, 2024 | Stephen H. Rusckowski Director | 1,551 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 29, 2024 | James L. Bierman Director | 1,551 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 29, 2024 | Meghan M. Fitzgerald Director | 1,551 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |